Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin

Despite improvements in treatment regimens for osteosarcoma (OS) patients, survival rate has not increased over the last two decades. New treatment modalities are therefore warranted. Preclinical results with conditionally replicative adenoviruses (CRAds) to treat OS are promising. One type of CRAd...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Graat, H C A, Witlox, M A, Schagen, F H E, Kaspers, G J L, Helder, M N, Bras, J, Schaap, G R, Gerritsen, W R, Wuisman, P I J M, van Beusechem, V W
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2006
Assuntos:
Translational Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361338/
https://ncbi.nlm.nih.gov/pubmed/16736005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603189
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares